Clinical trial · Interventional
Induced-T Cell Like NK Cells for B Cell Malignancies
Induced-T Cell Like NK Cellular Immunotherapy for Refractory B Cell Malignancies
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Relapsed and refractory B cell malignancies show unfavorable prognosis, especially for adult patients. Now, there is no standard management for these patients. Induced-T cell-like NK cells with chimeric antigen receptor (CAR-ITNK cells) is a promising treatment option for treating B cell derived malignancy. The purpose of this study is to evaluate the efficacy and safety of CAR-ITNK cells infusions in patients with relapsed and refractory B cell malignancies.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| B-cell Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia | ALIAS | 0.90 |
| B Cell Leukemia | Chronic Lymphocytic Leukemia | ALIAS | 0.90 |
| B Cell Lymphoma | B-Cell Malignant Neoplasm | CURATED_BROADER | 0.80 |
| B-cell Lymphoma Recurrent | — | UNRESOLVED | — |
| B-cell Lymphoma Refractory | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CAR-ITNK cells | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- ITNK group
- interventionNames
- Biological: CAR-ITNK cells
Primary outcomes (1)
- measure
- Adverse Events
- timeFrame
- 12 months
Secondary outcomes (5)
- measure
- ORR
- timeFrame
- 3 months
- description
- Overall Response Rate includes Complete Remission (CR) and Complete Remission with Incomplete Blood Count Recovery (CRi), as determined by assessments of peripheral blood, bone marrow, CNS symptoms, physical exam (PE) and CSF. The primary endpoint will be based on the IRC assessment. The local investigator's assessed results will be used for sensitivity analysis.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * Patient with CD19 positive B-cell acute leukemia * Eastern Cooperative Oncology Group (ECOG) performance status \<2 * ALT/ AST \<3 x normal * Bilirubin \< 2.0 mg/dl * Creatinine \< 2.5 mg/dl and less than 2.5x normal for age * LVEF\< 45% * Accept white blood cell collection * Provide informed consent Exclusion Criteria: * Previous treatment with investigational gene or cell therapy medicine products * Active hepatitis B , hepatitis C or HIV infection * Uncontrolled active infection * Presence of grade 2-4 acute or extensive chronic GVHD * Active CNS involvement: epilepsy, paresis, aphasia, stroke, severe head trauma, * Dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, uncontrolled mental illness, etc. * Any uncontrolled active medical disorder that would preclude participation as outlined. * Received non-diagnostic purposes major surgery within the past 4 weeks * Participated in any other clinical study within the past 4 weeks * Used murine biological products (except blinatumomab), unless it is proved no anti-mouse antibodies exist. * Pregnancy or breast-feeding women * Use of prohibited drugs: * Steroids: Therapeutic doses of steroids must be stopped \> 72 hours prior to ITNK Cells infusion * Allogeneic cellular therapy: Any donor lymphocyte infusions (DLI) must be completed \> 4 weeks prior to ITNK Cells infusion * GVHD therapies: Any drug used for GVHD must be stopped \> 4 weeks prior to ITNK Cells infusion * Any situation that may increase the risk of the test or interfere with the test results
References
Publications (0)
Data not yet available